12,391
Total Claims
$3.2M
Drug Cost
1,277
Beneficiaries
$2,508
Cost/Patient
Peer Comparison vs. 18,720 Cardiology providers
+65%
Cost per patient vs peers
$2,508 vs $1,524 avg
+70%
Brand preference vs peers
23.2% vs 13.7% avg
Brand vs Generic
77% generic
Brand: 2,871 claims · $2.8M
Generic: 9,504 claims · $450K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 642 | $525K |
| Rivaroxaban | 429 | $414K |
| Riociguat | 21 | $285K |
| Empagliflozin | 228 | $249K |
| Semaglutide | 113 | $164K |
| Sacubitril/Valsartan | 156 | $157K |
| Evolocumab | 120 | $149K |
| Semaglutide | 87 | $104K |
| Ambrisentan | 34 | $100K |
| Dapagliflozin Propanediol | 91 | $95K |
| Ticagrelor | 108 | $80K |
| Pitavastatin Calcium | 136 | $69K |
| Nebivolol Hcl | 523 | $47K |
| Dronedarone Hcl | 39 | $41K |
| Dulaglutide | 34 | $35K |
Prescribing Profile
Patient Profile
76
Avg Age
55%
Female
1.72
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data